mProX™ Human IRAK1 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1172	Magic™ Human IRAK1 in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

IRAK1

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

Jurkat; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Autoimmune Research; Infectious Research; Inflammation Research

Related Diseases

Pediatric Systemic Lupus Erythematosus and Mumps. Among its related pathways are MyD88 dependent cascade initiated on endosome and Bacterial infections in CF airways

Gene ID

3654

UniProt ID

P51617

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Encoded by the IRAK1 gene in humans, interleukin-1 receptor-associated kinase 1 (IRAK-1) is an enzyme. The immune system's ability to eradicate bacteria, viruses, and other pathogens is aided by immune cells like monocytes and macrophages, which express inflammatory genes under the control of IRAK-1. IRAK-1 is a member of the IRAK family, which also includes IRAK-2, IRAK-3, and IRAK-4. During a pathogenic attack, signaling pathways produce inflammatory chemicals that activate IRAK-1. Kinase enzymes, such as IRAK-1, control pathways in the innate and adaptive immune systems. Rheumatoid arthritis is associated with signaling through IRAK-1. Furthermore, IRAK-1 contributes significantly to cancer. The customized IRAK1 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Ronald

The human IRAK1 overexpression cell line has become a crucial tool in our lab, helping us gain deeper insights into angiogenesis and related processes. Sep 26 2020

chat Verified Customer

chat Amy

I can confidently say that the IRAK1 cell line is a fantastic tool. Nov 04 2021

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Effect of IRAK1/4-inh on T-ALL cell lines.

Following a 48-hour therapy, a notable reduction in IRAK1 phosphorylation was seen, indicating the inhibitor's pharmacological action. Nevertheless, compared to genetic knockdown, the apoptotic impact and reduction in proliferation instigated in the Jurkat cell-line upon IRAK1 inhibition were not as marked by pharmacologic inhibition.

Ref: Dussiau, Charles, et al. "Targeting IRAK1 in T-cell acute lymphoblastic leukemia." Oncotarget 6.22 (2015): 18956.

Pubmed: 26068967

DOI: 10.18632/oncotarget.4150

Research Highlights

Through NF-κB-related cytokine production, IRAK1 overexpression gives TNBC a growth advantage. Additionally, metastatic TNBC cells show an increase in IRAK1 reliance, making them highly susceptible to IRAK1 suppression through genetic and pharmacological means.
Wee, Zhen Ning, et al. "IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel." Nature communications 6.1 (2015): 8746.
Pubmed: 26503059 DOI: 10.1038/ncomms9746

Preliminary results from IRAK-targeted treatments that have advanced to early phase trials are encouraging. Studies on IRAK kinase signaling, however, continue to challenge accepted signaling theories and cast doubt on the best ways to treat patients.
Bennett, Joshua, and Daniel T. Starczynowski. "IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies." Current Opinion in Hematology 29.1 (2022): 8.
Pubmed: 34743084 DOI: 10.1097/MOH.0000000000000693